Cardiology

65-80 of 266

VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
Cardiology
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
- Carolyn Lam, MD
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
Cardiology
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
- Stephen Greene
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
Cardiology
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
- Justin Ezekowitz, MD, MBBCh, MSc
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Heart Matters
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Heart Matters
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Improving Lipid Management Through Equity-Focused Clinical Strategies
Improving Lipid Management Through Equity-Focused Clinical Strategies
Heart Matters
Improving Lipid Management Through Equity-Focused Clinical Strategies
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Heart Matters
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Heart Matters
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Cardiology
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
- Kausik Ray, MBChB, MD, MPhil
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
Cardiology
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
- Kausik Ray, MBChB, MD, MPhil
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
Cardiology
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Cardiology
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Cardiology
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
- Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Cardiology
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Heart Matters
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
- Kevin Alexander, MD
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Heart Matters
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
- Kevin Alexander, MD

5/10

65-80 of 266

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy